Defective DNA mismatch repair in long-term (≥ 3 years) survivors with pancreatic cancer
- 1 January 2005
- journal article
- Published by Elsevier BV in Pancreatology
- Vol. 5 (2-3), 220-228
- https://doi.org/10.1159/000085275
Abstract
Defective DNA mismatch repair (MMR) in pancreatic cancer, reported in up to 13% of sporadic pancreatic cancers, may predict a good prognosis. To determine if long-term survival in pancreatic cancer could be attributed to defective DNA MMR, we ascertained its prevalence in 35 pancreatic cancer patients who survived > or =3 years after surgery. We performed immunohistochemistry (IHC) for MMR proteins hMLH1, hMSH2, and hMSH6 in all 35 tumors and microsatellite instability (MSI) studies in 34/35 tumors using 10 microsatellite markers in paired normal and tumor DNA. Defective DNA MMR was defined as absence of protein expression on IHC and/or MSI in > or =30% of markers studied. On IHC, 3/35 (8.6%) tumors had defective DNA MMR. All 3 had absent expression of a DNA MMR protein (hMLH1 in 2 and hMSH2) and 2/3 also had MSI; the third could not be tested. Definitely 2, and probably all 3 patients had hereditary nonpolyposis colon cancer as determined by clinical and genetic profiles. Defective DNA MMR is uncommon in long-term survivors of pancreatic cancer and does not account for the survival benefit in those with sporadic pancreatic cancer.Keywords
This publication has 32 references indexed in Scilit:
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Mouse models of pancreatic cancer: The fur is finally flying!Cancer Cell, 2004
- Hereditary nonpolyposis colorectal cancer and related conditionsAmerican Journal of Medical Genetics Part A, 2003
- A “catastrophic hypothesis” for pancreas cancer progressionGastroenterology, 2003
- Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancersOncogene, 2002
- Focus on pancreas cancerCancer Cell, 2002
- Molecular prognostic markers in pancreatic cancerJournal of Hepato-Biliary-Pancreatic Surgery, 2002
- Involvement ofhMSH6in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivationInternational Journal of Cancer, 2001
- American Gastroenterological Association medical position statement: Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinomaGastroenterology, 1999
- Pancreatic Cancer Cell DNA Content Correlates With Long-term Survival After PancreatoduodenectomyAnnals of Surgery, 1991